Influenza Virus Production in an Amniocyte-Derived Human Cell Line

Many challenges are encountered within Existing Biopharmaceutical Production Systems. For example, optimization for antibody production but often the yields for complex proteins are very low. There is also a lack of correct post-translational modifications, limited to non-human/ immunogenic post translational modifications. The different production systems and therefore protein qualities, also present a challenge. What other challenges face vaccine production? Tell …